¼¼°èÀÇ ÀÓ»ó½ÃÇè °ü¸® ½Ã½ºÅÛ(CTMS)ÀÇ ½ÃÀå
Clinical Trial Management Systems (CTMS)
»óǰÄÚµå : 1513942
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 208 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,056,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,169,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀÓ»ó½ÃÇè °ü¸® ½Ã½ºÅÛ(CTMS)ÀÇ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 45¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2023³â¿¡ 17¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀÓ»ó½ÃÇè °ü¸® ½Ã½ºÅÛ(CTMS) ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 45¾ï ´Þ·¯¿¡ À̸£°í, ºÐ¼® ±â°£ 2023-2030³â CAGRÀº 14.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¿£ÅÍÇÁ¶óÀÌÁî ¿ÍÀ̵å CTMS´Â CAGR 15.0%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 31¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇöÀå CTMS ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ÀÇ CAGR·Î 13.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 7,790¸¸ ´Þ·¯, Áß±¹Àº CAGR 13.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ ÀÓ»ó½ÃÇè °ü¸® ½Ã½ºÅÛ(CTMS) ½ÃÀåÀº 2023³â 4¾ï 7,790¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2023³âºÎÅÍ 2030³â±îÁö 13.7%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 6¾ï 8,490¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, °¢°¢ ºÐ¼® ±â°£ Áß¿¡ 12.6%¿Í 12.0%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 10.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÓ»ó½ÃÇè °ü¸® ½Ã½ºÅÛ(CTMS) - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ

ÀÓ»ó½ÃÇè °ü¸® ½Ã½ºÅÛ(CTMS)Àº ÀÓ»ó½ÃÇè°ú °ü·ÃµÈ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ÇÁ·Î¼¼½º¸¦ ¿øÈ°ÇÏ°Ô °ü¸®ÇÒ ¼ö ÀÖ´Â Çö´ëÀÇ Àӻ󿬱¸¿¡ ÇʼöÀûÀÎ µµ±¸·Î µîÀåÇß½À´Ï´Ù. CTMS Ç÷§ÆûÀº ÀÓ»ó½ÃÇè °èȹ, ÃßÀû, °ü¸® µî ´Ù¾çÇÑ ±â´ÉÀ» ÅëÇÕÇÏ¿© ÀÓ»ó½ÃÇèÀÌ È¿À²ÀûÀ¸·Î ¼öÇàµÇ°í ±ÔÁ¦ ¿ä°ÇÀ» ÁؼöÇÏ¸ç ³ôÀº ¼öÁØÀÇ µ¥ÀÌÅÍ ¹«°á¼ºÀ» À¯ÁöÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ½ÃÇè ¼³Á¤, ´ë»ó µî·Ï, ¹æ¹® ÃßÀû, µ¥ÀÌÅÍ °ü¸®, º¸°í µîÀÇ ±â´ÉÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â´ÉÀ» Áß¾Ó ÁýÁßÈ­ÇÔÀ¸·Î½á CTMS´Â ½ÃÇèÀÇ ÁøÇà »óȲÀ» Àü¹ÝÀûÀ¸·Î ÆÄ¾ÇÇϰí ÀÌÇØ °ü°èÀÚ°£ÀÇ Á¶Á¤À» °­È­ÇÏ°í °ü¸® ¾÷¹«¸¦ ÇÕ¸®È­ÇÏ¸ç °á±¹ ÀÓ»ó ¿¬±¸¿Í °ü·ÃµÈ ½Ã°£°ú ºñ¿ëÀ» ÁÙÀÔ´Ï´Ù. ÀÌ Á¾ÇÕÀûÀÎ Á¢±ÙÀº ´õ ³ªÀº ÀÇ»ç °áÁ¤°ú ÀÚ¿ø ¹èºÐÀ» ÃËÁøÇÒ»Ó¸¸ ¾Æ´Ï¶ó »õ·Î¿î ¹®Á¦¿¡ ´ëÇÑ ½Å¼ÓÇÑ ´ëÀÀ ´É·ÂÀ» Çâ»ó½Ãŵ´Ï´Ù.

CTMSÀÇ µµÀÔÀº ±â¼úÀÇ Áøº¸¿Í ÀÓ»ó½ÃÇèÀÇ º¹ÀâÈ­¿¡ ÀÇÇØ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÃֽŠCTMS Ç÷§ÆûÀº ÀΰøÁö´É, ¸Ó½Å·¯´×, °í±Þ ºÐ¼® µîÀÇ Ã·´Ü ±â¼úÀ» Ȱ¿ëÇÏ¿© º¸´Ù °íµµ·Î ¿¹ÃøÀûÀÎ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, AI°¡ žÀçµÈ CTMS´Â ÀáÀçÀûÀÎ Áö¿¬À» ¿¹ÃøÇϰí, ¸ðÁýÀÇ º´¸ñ Çö»óÀ» ÆÄ¾ÇÇϰí, ÃÖÀûÀÇ ÀÚ¿ø ¹èºÐ Àü·«À» Á¦¾ÈÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ CTMS¿Í ÀüÀÚ ÀÇ·á ±â·Ï(EHR) ¹× ±âŸ ÀÇ·á IT ½Ã½ºÅÛ°úÀÇ ÅëÇÕÀ» ÅëÇØ ½Ç½Ã°£ µ¥ÀÌÅÍ °øÀ¯ ¹× ÀÓ»ó½ÃÇè µ¥ÀÌÅÍÀÇ Á¤È®¼º°ú ¹«°á¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ¾î À¯¿ë¼ºÀÌ ´õ¿í È®´ëµË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÇÕÀº ÀϰüµÈ µ¥ÀÌÅÍ ¼öÁý ¹× °ü¸®°¡ Áß¿äÇÑ ´ÙÁß ½Ã¼³ ÀÓ»ó½ÃÇè¿¡¼­ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ºÐ»êÇü ÀÓ»ó½ÃÇè(DCT)ÀÇ µ¿Çâµµ CTMSÀÇ Á߿伺À» µ¸º¸ÀÌ°Ô ÇÕ´Ï´Ù. CTMS´Â ¿ø°Ý ¸ð´ÏÅ͸µ°ú °ü¸®¸¦ ¿ëÀÌÇÏ°Ô ÇÏ°í ´Ù¾çÇÑ ÀÓ»ó½ÃÇè½Ã¼³ ½Ã¼³ °£ÀÇ ¿¬¼Ó¼º°ú ÄÄÇöóÀ̾𽺸¦ º¸ÀåÇϱ⠶§¹®ÀÔ´Ï´Ù.

ÀÓ»ó½ÃÇè°ü¸®½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ¾ß±âµË´Ï´Ù. ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í »õ·Î¿î Ä¡·á¹ýÀÇ ±ä±ÞÇÑ Çʿ伺¿¡ ÈûÀÔ¾î ÀÓ»ó½ÃÇè ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó È¿À²ÀûÀÎ ÀÓ»ó½ÃÇè °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷Àº R&D¿¡ ¾öû³­ ÅõÀÚ¸¦ Çϰí ÀÖÀ¸¸ç, ÷´Ü CTMS Ç÷§ÆûÀÇ Çʿ伺À» ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù. CTMS´Â ¾ö°ÝÇÑ ¹®¼­È­ ¹× º¸°í ±âÁØÀ» À¯ÁöÇÏ´Â µ¥ µµ¿òÀÌ µÇ¹Ç·Î ±ÔÁ¦ ¿ä°Ç°ú GCP(ÀǾàǰ ÀÓ»ó½ÃÇè ½Ç½Ã ±âÁØ) ¹× ICH(±¹Á¦ÀǾàǰÆò°¡Á¶È­À§¿øÈ¸) °¡À̵å¶óÀÎ µî ±âÁØ ÁؼöÀÇ Çʿ伺 ½ÉÁö¾î Áß¿äÇÑ ÃËÁø¿äÀÎÀ̵Ǿú½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚ Áß½ÉÀÇ ÀÓ»ó½ÃÇè°ú ¸ÂÃãÇü ÀÇ·á·ÎÀÇ ÀüȯÀÌ ´Ù¾çÇÏ°í ¿ªµ¿ÀûÀÎ ½ÃÇè ¼³°è¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â º¸´Ù ÀûÀÀ¼ºÀÌ ³ô°í À¯¿¬ÇÑ CTMS ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ²ø¾î¿Ã¸®°í ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý CTMSÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ´Â °Íµµ Áß¿äÇÑ ¿äÀÎÀ̸ç, È®À强 Çâ»ó, IT ºñ¿ë Àý°¨, Á¢±Ù¼º Çâ»óÀÌ ½ÇÇöµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÃËÁø¿äÀÎÀº ÀÓ»ó½ÃÇè °úÁ¤À» ÃÖÀûÈ­ÇÏ°í ±ÔÁ¦ ±ÔÁ¤ Áؼö¸¦ º¸ÀåÇÏ¸ç ±Ã±ØÀûÀ¸·Î »õ·Î¿î Ä¡·á¹ý ½ÃÀå ÁøÀÔÀ» °¡¼ÓÈ­ÇÏ´Â µ¥ CTMS°¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÑ´Ù´Â °ÍÀ» µÞ¹ÞħÇÕ´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñ 71»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Clinical Trial Management Systems (CTMS) Market to Reach US$4.5 Billion by 2030

The global market for Clinical Trial Management Systems (CTMS) estimated at US$1.7 Billion in the year 2023, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 14.5% over the analysis period 2023-2030. Enterprise-Wide CTMS, one of the segments analyzed in the report, is expected to record a 15.0% CAGR and reach US$3.1 Billion by the end of the analysis period. Growth in the On-Site CTMS segment is estimated at 13.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$477.9 Million While China is Forecast to Grow at 13.7% CAGR

The Clinical Trial Management Systems (CTMS) market in the U.S. is estimated at US$477.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$684.9 Million by the year 2030 trailing a CAGR of 13.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.6% and 12.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.3% CAGR.

Clinical Trial Management Systems (CTMS) - Key Trends and Drivers

Clinical Trial Management Systems (CTMS) have emerged as indispensable tools in the modern clinical research landscape, enabling seamless management of the complex, multifaceted processes involved in clinical trials. CTMS platforms integrate various functions such as trial planning, tracking, and management, ensuring that clinical trials are conducted efficiently, adhere to regulatory requirements, and maintain high standards of data integrity. These systems offer features like study setup, subject enrollment, visit tracking, data management, and reporting. By centralizing these functions, CTMS provides a holistic view of trial progress, enhances coordination among stakeholders, and streamlines administrative tasks, ultimately reducing the time and cost associated with clinical research. This comprehensive approach not only facilitates better decision-making and resource allocation but also enhances the ability to respond to emerging issues swiftly.

The adoption of CTMS has been accelerated by advancements in technology and the increasing complexity of clinical trials. Modern CTMS platforms are leveraging cutting-edge technologies such as artificial intelligence, machine learning, and advanced analytics to provide more sophisticated and predictive insights. For instance, AI-powered CTMS can predict potential delays, identify recruitment bottlenecks, and suggest optimal resource allocation strategies. Additionally, the integration of CTMS with electronic health records (EHR) and other healthcare IT systems has further expanded their utility, enabling real-time data sharing and improving the accuracy and completeness of clinical trial data. These integrations are particularly valuable in multi-center trials where consistent data collection and management are critical. The trend towards decentralized clinical trials (DCTs) has also highlighted the importance of CTMS, as these systems facilitate remote monitoring and management, ensuring continuity and compliance across various trial sites.

The growth in the Clinical Trial Management Systems market is driven by several factors. The increasing number of clinical trials, fueled by the rising prevalence of chronic diseases and the urgent need for new therapies, has created a robust demand for efficient trial management solutions. The pharmaceutical and biotechnology industries are heavily investing in research and development, further propelling the need for advanced CTMS platforms. Regulatory requirements and the need for compliance with standards such as Good Clinical Practice (GCP) and the International Council for Harmonisation (ICH) guidelines are also significant drivers, as CTMS helps in maintaining rigorous documentation and reporting standards. Additionally, the shift towards patient-centric trials and personalized medicine is pushing the demand for more adaptive and flexible CTMS solutions that can cater to diverse and dynamic trial designs. The growing adoption of cloud-based CTMS is another critical factor, offering enhanced scalability, reduced IT costs, and improved accessibility. These drivers collectively underscore the essential role of CTMS in optimizing clinical trial processes, ensuring regulatory compliance, and ultimately accelerating the delivery of new treatments to the market.

Select Competitors (Total 71 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â